Head & Neck Cancer

The immunotherapy Keytruda (pembrolizumab), in a recent study, proved twice as effective for the treatment of head and neck cancer as Erbitux (cetuximab), the only targeted therapy indicated as a therapy for the disease.

Jeannie Woith, BSN, RN, LMT, The James Cancer Hospital, The Ohio State University, discusses the treatment of oral mucositis in patients with head and neck cancer.

Thanks to The Cancer Genome Atlas (TCGA) Research Network, researchers now have a better understanding of genomic alternations in head and neck cancers.

Cases of HPV-related cancers are on the rise, specifically those associated with head and neck and anal cancers.

In the right cancer, radiation and chemotherapy can make a powerful duo.

Although there are advances in treating cancers linked to the human papillomavirus (HPV), the best medicine is to prevent the disease in the first place.

HPV causes surge in oral cancer rates.

The latest in cancer prevention, diagnosis and treatment.

HPV-positive oral cancers are on the rise.

Acupuncture reduces pain and dry mouth in head and neck cancer patients.

Cancer patients are living longer, but if radiation was part of their treatment, late effects may be a problem.

The insecurity and insight that come from cancer's battle scars.

Chronic inflammation causes cancer. Find out how and what's being done about it.

A number of diagnostic, prognostic, or predictive tests can help determine the optimal course of treatment by using predictive markers from the patient’s or tumor’s genetic information.

Minimally invasive technologies transform the landscape of cancer surgery.

Updates from the 2007 meeting of the American Society of Clinical Oncology includes news on liver, kidney, lung, colon, pancreatic and breast cancers.

New approvals for colorectal, lung, breast, head & neck cancer and lymphoma.

Updates from the 2006 annual meeting of the American Society of Clinical Oncology.

Revlimid is approved for certain types of myelodysplastic syndrome, and Sutent was approved for both advanced kidney cancer and gastrointestinal stromal tumor.

New therapies may turn the tide for this disfiguring cancer.